Vera Therapeutics Inc.
- Address
- 2000 Sierra Point Parkway Suite 1200
Sponsor Overview
Specializations
IgA Nephropathy and Berger Disease
Vera Therapeutics Inc. focuses on clinical research in IgA nephropathy, also referred to as Berger disease, with studies centered on kidney inflammation and proteinuria in both adults and pediatric populations.
- IgA nephropathy
- Berger disease
- Proteinuria
The sponsor’s trial portfolio includes work in patients with active renal disease and ongoing interest in clinical outcomes relevant to glomerular injury.
Multiple Autoimmune Glomerular Diseases
Research activity also extends to multiple autoimmune glomerular diseases, reflecting interest in immune-mediated kidney disorders that affect the renal and urinary system.
- Autoimmune glomerular disease
- Renal and urinary disorders
- Kidney inflammation
These studies address disease mechanisms linked to glomerulonephritis and related renal conditions requiring targeted therapeutic development.
Atacicept in Renal Immunology
The sponsor’s clinical program is built around atacicept, with trials examining its role in immune-mediated kidney disease and its effects on markers associated with IgA nephropathy.
- Atacicept
- Immune-mediated kidney disease
- Gd-IgA1
Key areas of interest include renal biomarker response and the management of chronic glomerular disease.
Pediatric Nephrology
Vera Therapeutics Inc. also supports research in pediatric nephrology, with attention to children affected by IgA nephropathy and the clinical characterization of treatment response in younger patients.
- Pediatric cohorts
- Childhood IgA nephropathy
- Renal safety and tolerability
This area reflects therapeutic interest in kidney disease across age groups, including long-term management of chronic renal disorders.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Atacicept in Adult Patients with IgA Nephropathy: A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Study |  Belgium Croatia Czechia Denmark Estonia France Germany Greece Ireland Italy Poland Portugal Spain | Not Recruiting |
| Evaluation of Atacicept Administration on Gd-IgA1 Levels in Patients with IgA Nephropathy: A Monthly Dosing Study | Poland Spain | Not Recruiting |
| Evaluation of Atacicept for Safety and Efficacy in Patients with Multiple Autoimmune Glomerular Diseases: A Phase 2 Clinical Trial | Belgium France Germany Italy Poland Spain | Recruiting |
| Long-Term Safety and Efficacy Evaluation of Atacicept in Patients with IgA Nephropathy Following Completion of Parent Study Treatment Period | Belgium Czechia Germany Greece Poland Spain | Recruiting |
Data & Insights
This sponsor works with 3 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 72 sites across their trial portfolio.
Therapeutic Focus
- 1.Pathological Conditions, Signs and Symptoms4 trials91 other sponsors
Partnered Research Centres
72 centres- Address
- Ul. Rudolfa Weigla 5, 53-114 Wroclaw
- Address
- Moelleparkvej 4, 9000 Aalborg
- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Deltalaan 1, 8800 Roeselare
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Via Cherasco 15, 10126 Turin
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Vera Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.